US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

49.91

-1.6000-3.11%

Post-market: 49.910.00000.00%19:30 EDT

Volume:13.25K

Turnover:667.54K

Market Cap:47.41M

PE:- -

High:50.89

Open:50.85

Low:49.91

Close:51.51

52wk High:56.18

52wk Low:23.81

Shares:950.00K

Float Shares:950.00K

Volume Ratio:1.54

T/O Rate:1.39%

Dividend:0.65

Dividend Rate:1.31%

ROE:--

ROA:--

PB:1.07

PE(LYR):- -

Loading ...

Overview Company News Filings

Glacial Melt Swells Rivers, Himalayan Floods Trigger Landslide on China-Nepal Border

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

Global Average Sea Surface Temperature Reaches Unprecedented High, Potentially Warmest Since the Last Interglacial Period

Savara announces presentations of Results from Phase 3 trial of Molgramostim

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY

TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials

Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer

Cullinan, Taiho say results of Phase 3 trial selected for presentation

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

Amylyx announces Lucidity Phase 3 trial met primary endpoint

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/BBC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":49.91,"timestamp":1789070400000,"preClose":51.51,"halted":0,"volume":13250,"hourTrading":{"tag":"盘后","latestPrice":49.91,"preClose":49.91,"latestTime":"19:30 EDT","volume":22,"amount":1105.95,"timestamp":1789083026465,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.031061929722384033,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Not Yet Opened","change":-1.6,"latestTime":"09-10 16:00:00 EDT","open":50.85,"high":50.89,"low":49.91,"amount":667535.3975,"amplitude":0.019025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":51.51,"sharesOutstanding":900004,"nav":51.382,"aum":48812941.17,"dividendRate":0.013104,"bidAskSpread":0.001886,"postHourTrading":{"tag":"盘后","latestPrice":49.91,"preClose":49.91,"latestTime":"19:30 EDT","volume":22,"amount":1105.95,"timestamp":1789083026465,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.539731,"impliedVol":0.3223,"impliedVolPercentile":0.444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.539731,"shares":950000,"dividePrice":0.654,"high":50.89,"amplitude":0.019025,"preClose":51.51,"low":49.91,"week52Low":23.81,"pbRate":"1.07","week52High":56.18,"institutionHeld":0,"latestPrice":49.91,"eps":0,"divideRate":0.013104,"volume":13250,"delay":0,"ttmEps":0,"open":50.85,"prevYearClose":38.56,"prevWeekClose":53.71,"prevMonthClose":53.05,"prevQuarterClose":52.6861,"fiveDayClose":53.78,"twentyDayClose":53.0562,"sixtyDayClose":43.6342},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1194965158","title":"Glacial Melt Swells Rivers, Himalayan Floods Trigger Landslide on China-Nepal Border","url":"https://stock-news.laohu8.com/highlight/detail?id=1194965158","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194965158?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:50","pubTimestamp":1787737854,"startTime":"0","endTime":"0","summary":"A flash flood, attributed to a sudden surge in river levels from melting snow, has wreaked havoc in Nepal's Rasuwa district, situated north of the capital Kathmandu and bordering China's Tibet region...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795913","title":"Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795913","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:52","pubTimestamp":1787730745,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","PSIL","BK4588","BBC","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107462297","title":"Global Average Sea Surface Temperature Reaches Unprecedented High, Potentially Warmest Since the Last Interglacial Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1107462297","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107462297?lang=en_us&edition=fundamental","pubTime":"2026-08-25 11:30","pubTimestamp":1787628645,"startTime":"0","endTime":"0","summary":"Multiple international media outlets reported on the 24th that data from the EU's Copernicus Climate Change Service revealed the average sea surface temperature in non-polar regions hit 21.1°C on...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BBC","IDNA","PSIL","SVRA","GDOC","BK4139","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729270","title":"Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662729270?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589063,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is moving ahead with MARITIME-2-EXTENSION, a Phase 3 trial that t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","BK4139","LU0058720904.USD","SG9999001440.SGD","BK4599","LU2089984988.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","BK4533","IE00B4R5TH58.HKD","LU2468319806.SGD","LU0122379950.USD","LU1983299246.USD","IBB","PBE","TBXU","LU0868494617.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","LU2112291526.USD","BK4585","IE00B2B36J28.USD","PSIL","LU1061106388.HKD","BK4588","BBC","IE0009355771.USD","AMGN","LU2242646821.SGD","LU0320765992.SGD","PJP","LU1023059063.AUD","BK4566","BK4534","LU2242652126.USD","BK4581","IBBQ","BIB","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294871","title":"Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294871?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:33","pubTimestamp":1787330033,"startTime":"0","endTime":"0","summary":"Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. has launched a Phase 2 trial testing felzartamab in adults wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","IE00B19Z9P08.USD","LU0320765992.SGD","BK4533","BIIB","IE00B894F039.SGD","LU0889565916.HKD","LU0234570918.USD","IE00B19Z9Z06.USD","BK4532","BK4585","PBE","BK4588","LU0109394709.USD","BK4139","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294820","title":"AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294820?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:30","pubTimestamp":1787329825,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s long-term Phase 2 trial NCT05443724, titled “A 52-week, Phase 2, Open-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IXJ","IE00BJT1NW94.SGD","LU0689626769.HKD","LU2023251221.USD","IE000F7OJYX1.SGD","XLV","BK4588","LU1934455863.HKD","BK4534","SG9999001440.SGD","LU0861579265.USD","LU1267930490.SGD","JDOC","SG9999003800.SGD","LU0310799852.SGD","PSIL","MEDX","LU2237443895.HKD","IE00B4R5TH58.HKD","LU0432979614.USD","LU0158827948.USD","LU0795875086.SGD","LU1244550494.USD","LU0256863811.USD","ISBC","GLAM","ABBV","LU0708994859.HKD","LU1989772840.SGD","LU1093756168.USD","LU0029864427.USD","PPH","LU0943347566.SGD","IYH","RXL","AGNG","IE00BN8TJ469.HKD","IE00B19Z3B42.SGD","IE0004445239.USD","BK4550","TRUH","LU1551013342.USD","FHLC","LU1003077747.HKD","LU0234570918.USD","LU1929549753.HKD","VHT","PJP","FTXH","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661975236","title":"Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661975236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661975236?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:30","pubTimestamp":1787243423,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview: Bayer has updated results from a terminated Phase 2 trial of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-adempas-trial-update-what-a-terminated-heart-lung-study-means-for-bayry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","PSIL","BBC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233036","title":"TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233036?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:18","pubTimestamp":1787239108,"startTime":"0","endTime":"0","summary":"An announcement from Evgen Pharma ( ($GB:TCF) ) is now available. TheraCryf plc has announced a proposed £1.05 million equity raise via a placing a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/theracryf-raises-1-05m-to-advance-addiction-drug-towards-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/theracryf-raises-1-05m-to-advance-addiction-drug-towards-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422820","title":"Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422820","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422820?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:16","pubTimestamp":1787156173,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) skyrocketed 133% on Wednesday after new data from a cancer vaccine Phase 3 trial showed strong results. Today’s gain marks one of t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/moderna-stock-mrna-soars-133-five-star-william-blair-analyst-says-strong-cancer-data-could-be-a-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGHT","MRNA","BK4139","BK4588","BK4548","BK4534","WDNA","PSIL","BK4501","IDNA","BK4568","GNOM","BK4551","BK4533","BK4585","BK4532","BBC","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422315","title":"Cullinan, Taiho say results of Phase 3 trial selected for presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422315?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:10","pubTimestamp":1787155816,"startTime":"0","endTime":"0","summary":"Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4139","BBC","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660538426","title":"Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660538426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660538426?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:36","pubTimestamp":1787146574,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals (BDRX) announced that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biodexa-recruits-87-of-168-subjects-in-serenta-phase-3-erapa-polyposis-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","BBC","BDRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425479","title":"Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425479","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425479?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:15","pubTimestamp":1787145349,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-moderna-skyrockets-after-cancer-vaccine-shows-promise-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PSIL","BK4195","PFS","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184678054","title":"Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184678054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184678054?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:15","pubTimestamp":1787127336,"startTime":"0","endTime":"0","summary":"Andy Acker, Portfolio Manager for healthcare and biotech strategies at Janus Henderson Investors, notes that despite interest rates remaining higher than markets anticipated at the start of the year,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","IYG","BBC","GTPE","BK4585","BIB","IJT","JDOC","FBT","BK4588","PBE","QSML","IAI","SPCK","IWO","IBB","BBP","BK4582","MRNY","BIS","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","BBC","NVIB","XBIX","BK4195","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","AMLX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609102","title":"argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609102?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:39","pubTimestamp":1786945177,"startTime":"0","endTime":"0","summary":"arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx has reported positive topline results from its ALKIVIA Phase 3 trial of VYVGART Hytrulo i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4139","BK4563","PSIL","SOCL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","MSB","BK4006","PSIL","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105196","title":"Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105196","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105196?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:24","pubTimestamp":1786926259,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial testing ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","MESO","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":136,"code":"91000000","status":"200"}]}}